Osteoarthritis (OA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Osteoarthritis (OA) Market Outlook
Thelansis’s “Osteoarthritis (OA) Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2024 To 2034" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Osteoarthritis
(OA) treatment modalities options for
eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Osteoarthritis
(OA) Overview
Osteoarthritis
(OA) is a complex condition characterized by progressive musculoskeletal pain
and restricted movement, often accompanied by the deterioration of articular
cartilage, changes in local bone structure, and the development of osteophytes.
This joint disorder manifests differently between men and women, highlighting
the importance of recognizing gender dimorphism for both prevention and
treatment strategies. These structural and anatomical distinctions can be
observed early and later in life, such as the thinner articular cartilage in
the distal femur of girls and women compared to boys and men, leading to joint
pain, capsule thickening, and osteophyte formation. Approximately 43.3% of
individuals experience persistent pain, aching, or stiffness associated with
osteoarthritis. The FDA has approved several drugs for the management of
osteoarthritis, including Duexis (ibuprofen and famotidine), Mobic (meloxicam),
Naprelan (naproxen sodium), Pennsaid (diclofenac sodium topical solution),
Vivlodex (meloxicam), and Zilretta (triamcinolone acetonide extended-release
injectable suspension).
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment